✦ LIBER ✦

Alemtuzumab in T-cell lymphoproliferative disorders

✍ Scribed by Claire E. Dearden; Estella Matutes

Book ID: 119195331
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 203 KB
Volume: 19
Category: Article
ISSN: 1521-6926
DOI: 10.1016/j.beha.2006.05.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab in chronic lymphocytic leuka

Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders

✍ M. Fiegl; G. Gastl; G. Hopfinger; K. Eigenberger; A. Zabernigg; T. Schenk; F. Fa 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 251 KB

Severe and prolonged myeloid haematopoie

Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders

✍ Simon D. J. Gibbs; David A. Westerman; Christopher McCormack; John F. Seymour; H 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Alemtuzumab therapy in B-cell lymphoprol

Alemtuzumab therapy in B-cell lymphoproliferative disorders

✍ Paul Moreton; Peter Hillmen 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Chronic T-cell lymphoproliferative disor

Chronic T-cell lymphoproliferative disorders

📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

Oncogene expression in T-cell lymphoprol

Oncogene expression in T-cell lymphoproliferative disorders

✍ Gayle E. Woloschak; W.Craig Hooper; Mary J. Doerge; Robert L. Phyliky; Thomas E. 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 893 KB

Phase II study of alemtuzumab in chronic

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

✍ Alessandra Ferrajoli; Susan M. O'Brien; Jorge E. Cortes; Francis J. Giles; Debor 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract ## BACKGROUND Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. ## METHODS Seventy‐eight patients